Mode
Text Size
Log in / Sign up

Multi-ancestry meta-analysis identifies X-chromosome loci for heart failure phenotypes

Multi-ancestry meta-analysis identifies X-chromosome loci for heart failure phenotypes
Photo by Logan Voss / Unsplash
Key Takeaway
Consider that X-chromosome variation may contribute to heart failure risk across ancestries, with sex-specific differences in detectable loci.

This multi-ancestry meta-analysis of X-chromosome variation used data from the Million Veteran Program (590,568 participants, including 90,694 HF cases) and the UK Biobank for replication. The analysis sought X-chromosome-wide significant loci for all-cause heart failure (HF), HF with reduced ejection fraction (HFrEF), and HF with preserved ejection fraction (HFpEF).

In multi-ancestry meta-analyses, five X-chromosome-wide significant loci were identified for all-cause HF and five for HFrEF. For HFpEF, one locus was identified in males. Sex-combined analyses yielded six loci for all-cause HF and four for HFrEF. In female-specific analyses, no loci reached significance. Ancestry-specific analyses identified additional loci in African ancestry (including NDP and WDR44) and Hispanic ancestry (including PHF8). Replication in the UK Biobank HF cohort supported one locus, BRWD3.

The authors acknowledge limitations, including the absence of effect sizes, absolute numbers, p-values, and confidence intervals in the provided results. The study does not establish causality, and the generalizability of findings across populations requires further investigation.

These findings suggest that X-chromosome variation contributes to HF risk across ancestries and sexes. The identified loci may inform future mechanistic studies, but clinical application awaits additional validation and characterization of the associated variants.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Background: Heart failure (HF) is a major and growing public health problem, and prior studies support a meaningful genetic contribution to HF susceptibility. Clinically, HF is commonly categorized into the major clinical sub-types of HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF), which differ in pathophysiology and clinical profiles. However, previous genome-wide association studies have focused on autosomal variation and have routinely excluded the X chromosome, leaving X-linked genetic contributions to HF and its subtypes under-characterized. Methods: We performed X-chromosome wide association study (XWAS) utilizing directly genotyped data from 590,568 Million Veteran Program participants, including 90,694 HF cases across European, African, Hispanic, and Asian Americans. Sex- and ancestry-stratified logistic regression was used with XWAS quality control measures, adjusting for age and population structure, followed by fixed-effects multi-ancestry meta-analysis. Functional annotation, gene-based testing, fine-mapping, and colocalization were performed. We replicated genetic associations with all-cause HF in the UK Biobank. Results: In the multi-ancestry meta-analysis, we identified five X-chromosome-wide significant loci for all-cause HF, five for HFrEF, and one locus for HFpEF in males. No loci reached significance in female-specific analyses. In sex-combined analyses, we identified six loci for all-cause HF and four for HFrEF. The strongest and most emphasized signals mapped to genes were BRWD3, FHL1, and CHRDL1. Ancestry-specific analyses revealed additional loci, including NDP and WDR44 in African ancestry and PHF8 in Hispanic ancestry. One locus, BRWD3, was replicated in UK Biobank HF cohort. Integrated post-GWAS analyses (fine-mapping, colocalization and pleiotropy trait association studies) reinforced the biological plausibility of the X-linked signals. Conclusions: This multi-ancestry, sex-stratified XWAS identifies X-linked genetic contributions to HF and its subtypes and highlights the role of X-chromosome in heart failure pathogenesis.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.